MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

SCH529074

CAS No. : 922150-11-6

MCE 国际站：SCH529074

产品活性：SCH529074 是一种具有口服活性的 p53 激活剂。SCH529074 与 p53 DBD 特异性结合并与构象相关，其 K_i 值为 1-2 μM。SCH529074 恢复突变的 p53 功能，并阻断 HDM2 介导的野生型 p53 泛素化。SCH529074 可用于非小细胞肺癌 NSCLC 的研究。

研究领域：Apoptosis

作用靶点：MDM-2/p53

In Vitro: SCH529074 (2-4 µM; 24 hours) causes significant reduction in cell viability, it causes a significant decreasing to 20-25% in p53 mutant cells (H157, H1975 and H322) and to 68% in the p53 WT cell line A549 at 4 µM.
SCH 529074 (2 and 4 µM) induces NSCLC cells (H157, A549, HCT116 and HCT116 p53^-/-) arrested at the G0/G1 phase (59%; 72%; 66%; and 57%) compared with the control cells following low concentration (2 µM) of treatment.
SCH 529074 (2-4 µM; 24 hours) induces the early and late apoptotic rates at 2 µM in H1975 cells. In H157 cells, SCH 529074 treatment induces early and late apoptosis. Similarly, in A549 cells, 2 and 4 µM of SCH 529074 significantly increased early and late apoptosis. In line with that, in colon cancer cells, in HCT116 cells, 4 µM of SCH 529074 causes a significant induction of early and late apoptosis, and 4 µM of SCH 529074 significantly induces early apoptosis in HCT116 p53^-/- cells.
SCH 529074 (2-6 µM; 24 hours) increases the protein levels of PUMA and p21 revealed to 4 or 6 µM in the cancer cell lines regardless of their p53 status.

In Vivo: SCH529074 (oral administration; 30 or 50 mg/kg; twice daily; 4 weeks; started on day 3 until day 31) causes 79 and 43% reduction of tumor growth at 50 and 30 mg/kg doses, respectively. the degree of tumor inhibition correlates with the plasma exposure of the compound (0.26–0.55 μm at 30 mg/kg and 0.39-0.79 μm at 50 mg/kg, 2-12 h post final dosing) in human DLD-1 colorectal cancer xenograft.

相关产品：Bioactive Compound Library Plus  |  Apoptosis Compound Library  |  Anti-Cancer Compound Library  |  Autophagy Compound Library  |  Anti-Aging Compound Library  |  Ferroptosis Compound Library  |  Pyroptosis Compound Library  |  Orally Active Compound Library  |  Glutamine Metabolism Compound Library  |  Anti-Lung Cancer Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Anti-Blood Cancer Compound Library  |  Anti-Cancer Metabolism Compound Library  |  Transcription Factor-Targeted Library  |  Anti-Colorectal Cancer Compound Library   |  Heterocyclic Compound Library  |  p53 (17-26)  |  p53 and MDM2 proteins-interaction-inhibitor (racemic)  |  Navtemadlin  |  Antitumor agent-60  |  Roslin 2 bromide  |  Amifostine trihydrate  |  MX69  |  ADH-6 TFA  |  RG7112  |  CBL0137 hydrochloride  |  MA242  |  MD-224  |  MB710  |  NSC59984  |  MDM2/4-p53-IN-1  |  Oxychlororaphine  |  Pifithrin-β hydrobromide  |  p53-MDM2-IN-1  |  PK11000  |  Tenovin-6  |  NSC 146109 hydrochloride  |  Ivaltinostat  |  FOXO4-DRI acetate  |  3-Morpholinosydnonimine  |  PROTAC MDM2 Degrader-1  |  Lobetyol  |  NSC405640  |  CP-31398 dihydrochloride  |  p53-HDM2-IN-1

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物  |  寡核苷酸  |  抗体  |  点击化学

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。